The Commitment Threshold

How Much Evidence Is Enough?

Leaders often demand certainty before committing significant resources.

But strategic opportunities rarely arrive with certainty.

The real question is:

What level of evidence should trigger commitment?

This is one of the most difficult questions in strategic allocation because waiting for sufficient evidence can feel responsible—until the evidence finally arrives after the opportunity has become more expensive, more competitive, or less accessible.

The challenge is not choosing between certainty and uncertainty.

It is determining how much uncertainty the organization is willing to fund.

The Evidence Paradox

Consider an emerging healthcare opportunity.

Leadership asks for:

More demand data.

More patient research.

More financial projections.

More competitive intelligence.

More proof of physician interest.

Reasonable?

Absolutely.

But some opportunities cannot produce compelling evidence until someone commits enough resources to create the conditions for that evidence to emerge.

This creates an evidence paradox:

The organization wants proof before investing—but the proof may require investment.

Harvard Business Review has described this challenge as an “information-action paradox”: in uncertain markets, the information needed to justify a decision may only become clear when it is too late to act.

That means waiting for certainty can become a strategic decision in itself.

Not Every Decision Deserves the Same Evidence

A $50,000 exploratory initiative should not require the same evidence as a $50 million capital commitment.

Yet organizations often treat strategic decisions as binary:

Approve.

or

Reject.

A more sophisticated approach recognizes levels of commitment.

Explore → Test → Build → Scale

Each stage should require a different evidence threshold.

A small pilot may require evidence that a meaningful customer need exists.

Scaling may require evidence of demand, economics, operational feasibility and strategic fit.

The question becomes:

What evidence is sufficient for this level of commitment?

McKinsey's work on strategy under uncertainty similarly distinguishes between large commitments, lower-cost options and “no-regrets” moves, emphasizing that leaders can make smaller investments that preserve the ability to commit more later as uncertainty resolves.

The Danger of Requiring Proof Too Early

There is a subtle bias in evidence-driven organizations:

The evidence threshold can become so high that emerging opportunities never qualify.

This is particularly dangerous when competitors are learning faster.

Imagine two healthcare organizations evaluating an emerging specialty or technology.

Organization A waits for conclusive demand evidence.

Organization B funds a limited pilot, learns from actual patient behavior, develops internal capability and establishes relationships with key talent.

Organization B may eventually have better evidence—not because it predicted the future better, but because it started learning earlier.

McKinsey research on real options makes a similar point: staged investment can preserve flexibility while allowing organizations to learn before making larger commitments.

The strategic advantage may therefore belong not to the organization with the best forecast.

It may belong to the organization with the best learning architecture.

But There Is an Opposite Problem

Lowering the evidence threshold does not mean funding everything.

That simply creates another allocation failure.

Organizations can become enamored with emerging technologies, fashionable service lines or compelling growth narratives and continue investing despite weak evidence.

The answer is not:

“Act before you have enough information.”

It is:

“Define in advance what evidence will justify the next level of commitment.”

That distinction changes governance.

Instead of asking whether an initiative is successful enough to continue, leadership asks:

What did we expect to learn?

What have we learned?

What evidence would cause us to increase investment?

What evidence would cause us to stop?

McKinsey has found that organizations with more explicit thresholds for revisiting resource deployment can improve their ability to respond as evidence and uncertainty change.

Introducing Commitment Threshold™

Phoenix MedStrategy defines Commitment Threshold™ as:

The minimum level of evidence, strategic fit and opportunity signal required before an organization increases its resource commitment.

This creates a useful distinction between interest and commitment.

An opportunity can be strategically interesting without deserving significant resources.

It can also deserve an initial investment precisely because the investment will generate information that cannot be obtained through analysis alone.

The executive task is determining which is which.

The Provocative Questions

Healthcare leaders should ask:

Are we demanding proof from opportunities that can only be validated through investment?

What evidence would change our allocation decision?

Are we waiting for certainty that competitors will never have?

Where are we overfunding because evidence already exists?

Where are we underfunding because evidence cannot exist until we begin?

And perhaps the most important question:

What would have to be true before we double down?

That question forces leadership to define the conditions for increased commitment before organizational enthusiasm, sunk costs or internal politics begin influencing the answer.

The Threshold Test

Before increasing resources, leadership should be able to identify five things:

Signal — What evidence suggests the opportunity is real?

Strategic Fit — Does it strengthen the future position we want?

Learning — What has the organization discovered through initial action?

Trigger — What specific evidence would justify greater investment?

Exit — What evidence would tell us to stop?

This turns uncertainty from something leadership must eliminate into something leadership can manage deliberately.

The Phoenix Perspective

The goal is not to predict the future perfectly.

It is to create a leadership system capable of learning fast enough to invest intelligently before certainty arrives.

Some opportunities deserve immediate commitment.

Some deserve observation.

Some deserve a small investment designed to generate evidence.

The sophistication lies in knowing the difference.

At Phoenix MedStrategy, we help healthcare leaders determine not only where resources should go, but when the evidence is strong enough to increase commitment—and what should be learned before making the next move.

Because strategic discipline is not waiting until the future becomes obvious.

It is knowing what evidence should make you act before it does.

Sources

Harvard Business Review, “When You Have to Make a Strategic Decision Without Much Data,” 2024.

McKinsey & Company, “Strategy Under Uncertainty.”

McKinsey & Company, “The Real Power of Real Options.”

McKinsey & Company, “How Nimble Resource Allocation Can Double Your Company’s Value.”

McKinsey & Company, “Have You Tested Your Strategy Lately?”